AT
The startup develops small-molecule therapeutics that enhance mitochondrial function to treat rare lysosomal-storage disorders, including Parkinson's disease. Their therapeutics provide healthcare professionals with targeted options for managing neurodegenerative diseases, improving patient outcomes.
Updated 2 months ago
Funding
$16.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops small-molecule therapeutics that enhance mitochondrial function to treat rare lysosomal-storage disorders, including Parkinson's disease. Their therapeutics provide healthcare professionals with targeted options for managing neurodegenerative diseases, improving patient outcomes.